Abstract
An increasing body of clinical and experimental evidence suggesting that TNFα may play a pathogenetic role in failing hearts continues to accumulate. Perhaps the most direct evidence for the role of TNFα in heart failure will come from the analysis of the phase I study in which a soluble recombinant human TNF receptor: Fc fusion protein was utilized in patients with moderate to severe heart failure. Enrollment in that trial was recently completed; the results will soon be available for analysis. But perhaps more importantly, the knowledge gained from studying the role of TNFα in cardiac function draws attention to a series of molecules previously unrecognized as potential mediators in the pathogenesis of heart failure. Various cytokines and TNFα, in particular, represent new targets for therapeutic intervention in patients with heart failure.
Original language | English (US) |
---|---|
Pages (from-to) | 24-27 |
Number of pages | 4 |
Journal | Zeitschrift fur Kardiologie |
Volume | 88 |
Issue number | SUPPL. 3 |
DOIs | |
State | Published - 1999 |
Keywords
- Disease progression
- Heart failure
- Tumor necrosis factor-α
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine